Trial Site Detail

 

Drug:
CB-839
Trial:
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Conditions: Solid Tumors
Trial Status:
Active, not recruiting

 

H. Lee Moffit Cancer Center

12902 Magnolia Dr.     
Tampa , FL 33612
USA

 

Principal Investigator:
Andrew S. Brohl
Contact:
800-679-0775 canceranswers@moffitt.org
Activation Status of this Site:
Closed
Notes about this Site:
H. Lee Moffit Cancer Center Website:
http://www.moffitt.org/Site.aspx?spid=BF72D4455066450A96F788D72D1E2187&type=PhysSearchByProg&progname=Sarcoma&SearchType=Physician

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.